ATE163973T1 - Antisense oligonukleotidhemmung von papillomavirus - Google Patents
Antisense oligonukleotidhemmung von papillomavirusInfo
- Publication number
- ATE163973T1 ATE163973T1 AT91902031T AT91902031T ATE163973T1 AT E163973 T1 ATE163973 T1 AT E163973T1 AT 91902031 T AT91902031 T AT 91902031T AT 91902031 T AT91902031 T AT 91902031T AT E163973 T1 ATE163973 T1 AT E163973T1
- Authority
- AT
- Austria
- Prior art keywords
- papillomavirus
- oligonucleotide
- oligonucleotides
- antisense oligonucleotide
- oligonucleotide inhibition
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 10
- 241001631646 Papillomaviridae Species 0.000 title abstract 5
- 239000000074 antisense oligonucleotide Substances 0.000 title 1
- 238000012230 antisense oligonucleotides Methods 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 3
- 108020004999 messenger RNA Proteins 0.000 abstract 3
- 230000000692 anti-sense effect Effects 0.000 abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44519689A | 1989-12-04 | 1989-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE163973T1 true ATE163973T1 (de) | 1998-03-15 |
Family
ID=23767951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT91902031T ATE163973T1 (de) | 1989-12-04 | 1990-12-03 | Antisense oligonukleotidhemmung von papillomavirus |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0503002B1 (de) |
| JP (1) | JPH05501058A (de) |
| KR (1) | KR960012069B1 (de) |
| AT (1) | ATE163973T1 (de) |
| AU (1) | AU650257B2 (de) |
| BR (1) | BR9007892A (de) |
| CA (1) | CA2070664C (de) |
| DE (1) | DE69032134T2 (de) |
| FI (1) | FI922593A0 (de) |
| HU (1) | HUT62944A (de) |
| WO (1) | WO1991008313A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5447839A (en) * | 1988-09-09 | 1995-09-05 | Hoffmann-La Roche Inc. | Detection of human papillomavirus by the polymerase chain reaction |
| US5457189A (en) * | 1989-12-04 | 1995-10-10 | Isis Pharmaceuticals | Antisense oligonucleotide inhibition of papillomavirus |
| US5635488A (en) * | 1991-10-15 | 1997-06-03 | Isis Pharmaceuticals, Inc. | Compounds having phosphorodithioate linkages of high chiral purity |
| US5620963A (en) * | 1991-10-15 | 1997-04-15 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity |
| US5587361A (en) * | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US6339066B1 (en) | 1990-01-11 | 2002-01-15 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C |
| US5607923A (en) * | 1991-10-15 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity |
| US5599797A (en) * | 1991-10-15 | 1997-02-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US5661134A (en) * | 1991-10-15 | 1997-08-26 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity |
| US5654284A (en) * | 1991-10-15 | 1997-08-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity |
| US5576302A (en) * | 1991-10-15 | 1996-11-19 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity |
| US6537973B1 (en) | 1992-03-16 | 2003-03-25 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of protein kinase C |
| WO1995028942A1 (en) * | 1994-04-26 | 1995-11-02 | Genta Incorporated | Antisense oligomers for inhibiting human papillomaviruses |
| US5750341A (en) * | 1995-04-17 | 1998-05-12 | Lynx Therapeutics, Inc. | DNA sequencing by parallel oligonucleotide extensions |
| US6509149B2 (en) * | 1995-06-06 | 2003-01-21 | Hybridon, Inc. | HPV-specific oligonucleotides |
| US6458940B2 (en) * | 1995-06-06 | 2002-10-01 | Hybridon, Inc. | HPV-specific oligonucleotides |
| FR2758725B1 (fr) * | 1997-01-29 | 1999-04-02 | Pasteur Institut | Composition comprenant une proteine e2 de papillomavirus ou une sequence de nucleotides codant pour une proteine e2 de papillomavirus |
| JP5710977B2 (ja) * | 2007-11-05 | 2015-04-30 | バルティック テクノロジー デヴェロプメント，リミテッド | 抗ウイルス薬としての修飾塩基を含むオリゴヌクレオチドの使用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4806463A (en) * | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
| EP0357611B1 (de) * | 1987-02-26 | 1995-04-26 | The University Of Sydney | Verfahren zum nachweis des karzinogenen menschlichen papillomavirus |
| US4849332A (en) * | 1987-05-26 | 1989-07-18 | Life Technologies, Inc. | Human papillomavirus 35 nucleic acid hybridization probes and methods for employing the same |
| US4849331A (en) * | 1987-06-09 | 1989-07-18 | Life Technologies, Inc. | Human papillomavirus 44 nucleic acid hybridization probes and methods for employing the same |
| US4849334A (en) * | 1987-06-09 | 1989-07-18 | Life Technologies, Inc. | Human papillomavirus 43 nucleic acid hybridization probes and methods for employing the same |
| US4908306A (en) * | 1987-06-12 | 1990-03-13 | Life Technologies, Inc. | Human papillomavirus 56 nucleic acid hybridization probes and methods for employing the same |
| FR2629458B2 (fr) * | 1987-07-31 | 1991-08-09 | Ire Celltarg Sa | Nouvelles sondes d'acides nucleiques specifiques de differents types de virus de papillome humain |
| US4886741A (en) * | 1987-12-09 | 1989-12-12 | Microprobe Corporation | Use of volume exclusion agents for the enhancement of in situ hybridization |
| DE3838269A1 (de) * | 1988-11-11 | 1990-05-17 | Behringwerke Ag | Nachweis humaner papillomavirus dna und ihrer expression in zervix-abstrichen |
| US5027693A (en) * | 1989-11-24 | 1991-07-02 | Allied-Signal Inc. | Combination diaphragm and valve body |
| AU7302191A (en) * | 1990-01-30 | 1991-08-21 | Children's Hospital Of Los Angeles | Inhibition of transcription by double-stranded oligonucleotides |
-
1990
- 1990-12-03 JP JP91502693A patent/JPH05501058A/ja active Pending
- 1990-12-03 AT AT91902031T patent/ATE163973T1/de not_active IP Right Cessation
- 1990-12-03 FI FI922593A patent/FI922593A0/fi unknown
- 1990-12-03 CA CA002070664A patent/CA2070664C/en not_active Expired - Fee Related
- 1990-12-03 BR BR909007892A patent/BR9007892A/pt not_active Application Discontinuation
- 1990-12-03 DE DE69032134T patent/DE69032134T2/de not_active Expired - Fee Related
- 1990-12-03 EP EP91902031A patent/EP0503002B1/de not_active Expired - Lifetime
- 1990-12-03 HU HU921865A patent/HUT62944A/hu unknown
- 1990-12-03 KR KR1019920701324A patent/KR960012069B1/ko not_active Expired - Fee Related
- 1990-12-03 AU AU71756/91A patent/AU650257B2/en not_active Ceased
- 1990-12-03 WO PCT/US1990/007067 patent/WO1991008313A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| FI922593L (fi) | 1992-06-04 |
| EP0503002A4 (en) | 1993-03-10 |
| JPH05501058A (ja) | 1993-03-04 |
| EP0503002A1 (de) | 1992-09-16 |
| CA2070664C (en) | 2000-08-08 |
| DE69032134T2 (de) | 1998-07-23 |
| HUT62944A (en) | 1993-06-28 |
| BR9007892A (pt) | 1992-09-29 |
| AU650257B2 (en) | 1994-06-16 |
| FI922593A7 (fi) | 1992-06-04 |
| DE69032134D1 (de) | 1998-04-16 |
| FI922593A0 (fi) | 1992-06-04 |
| EP0503002B1 (de) | 1998-03-11 |
| HU9201865D0 (en) | 1992-09-28 |
| WO1991008313A1 (en) | 1991-06-13 |
| KR960012069B1 (ko) | 1996-09-12 |
| AU7175691A (en) | 1991-06-26 |
| CA2070664A1 (en) | 1991-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0637316A4 (de) | Antisense-oligonukleotide-inhibitoren von papillomaviren. | |
| ATE163973T1 (de) | Antisense oligonukleotidhemmung von papillomavirus | |
| ATE154029T1 (de) | 7-deazapurin modifizierte oligonukleotide | |
| ATE373671T1 (de) | Aminooxy-modifizierte oligonukleotide | |
| KR930700525A (ko) | 인체 면역결핍 바이러스의 안티센스 억제제 | |
| DE69230223D1 (de) | Antisense-oligonukleotid-inhibition des ras-gen | |
| FI925103A0 (fi) | Antisense-inhibitorer av humant immunbristvirus | |
| DE68925278D1 (de) | Hemmung von htlv-iii durch exogene oligonukleotide | |
| DE69829115D1 (de) | Zusammensetzungen und verfahren zur behandlung von hepatitis c virus-bedingten erkrankungen | |
| ATE112310T1 (de) | Hemmung von htlv-iii durch exogene oligonukleotide. | |
| ATE312202T1 (de) | Menschliche rnase h und entsprechende oligonukleotidverbindungen | |
| DE69330372D1 (de) | ZUSAMMENSETZUNGEN UND VERFAHREN FüR DIE BEHANDLUNG VON MIT HEPATITIS C VIREN ASSOZIIERTEN KRANKHEITEN | |
| DE69133511D1 (de) | Zuckermodifizierte oligonukleotide zum erkennen und steuern der genexpression | |
| DE69934227D1 (de) | Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide | |
| DE69032080D1 (de) | Verwendung von konservierten Oligonukleotid-Primern zur Amplifizierung von menschlichen Papillomavirus-DNS-Sequenzen | |
| EP1123414A4 (de) | Antisense modulation der expression von integrin alpha 4 | |
| NO965017L (no) | Oligonukleotider med anti-cytomegalovirus aktivitet | |
| ES2048652A1 (es) | Procedimientos de amplificacion de genoma para la deteccion e identificacion de secuencias genomicas relacionadas. | |
| NO922169L (no) | Antisensoligonukleotidinhibisjon av papillomavirus | |
| DE50303606D1 (de) | Decoy-oligonukleotid-hemmung der cd40-expression | |
| DE60014537D1 (de) | Dna polymerase aus i(pyrobaculum islandicum) | |
| WO1995030748A3 (en) | Plant u14 nucleic acid sequences and derivatives thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |